887 results match your criteria risk nmibc


Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.

Urol Oncol 2021 Apr 10. Epub 2021 Apr 10.

University of Colorado, Division of Urology, Aurora, CO; Yale University, Cancer Outcomes and Public Policy Effectiveness Research, (COPPER) Center, New Haven, CT. Electronic address:

Introduction: Radiation therapy (XRT) has been investigated as a possible treatment for high-risk non-muscle invasive bladder cancer (NMIBC) with the goal of bladder preservation, especially with the ongoing Bacillus Calmette-Guerin (BCG) shortage. Yet, little is known about the clinical efficacy and the quality of evidence supporting XRT for NMIBC. Herein, we performed a systematic review and meta-analysis to evaluate XRT in the treatment of patients with high-risk NMIBC. Read More

View Article and Full-Text PDF

Apparent Diffusion Coefficient Value can Predict Poor Bacillus Calmette-Guérin Responders in T1HG/NMIBC: Prospective Cohort Study.

Clin Genitourin Cancer 2021 Mar 17. Epub 2021 Mar 17.

Urology Department, Zagazig University, Zagazig, Egypt. Electronic address:

Background: Prediction of recurrence and progression and the choice of type of management are largely based on stage and grade; however, these prognostic features are limited in the prediction of clinical outcomes. The objective was to investigate the relation between the apparent diffusion coefficient (ADC) value and recurrence and progression of T1G3 of urothelial carcinoma after transurethral resection of the bladder tumor (TURBT) and Bacillus Calmette-Guérin instillation.

Materials And Methods: This prospective study included 65 patients with single bladder mass T1G3 less than 3 cm without carcinoma in situ or lymphovascular invasion. Read More

View Article and Full-Text PDF

The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.

Cancer Manag Res 2021 31;13:2937-2945. Epub 2021 Mar 31.

Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a potentially curable or controllable disease if strict adherence to a surveillance protocol is followed. Management and surveillance of NMIBC begins at the time of diagnosis up to a few years thereafter. There is scanty data in the literature evaluating the impact of non-compliance with the surveillance protocols on progression, recurrence, and mortality rate. Read More

View Article and Full-Text PDF

Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?

World J Urol 2021 Apr 8. Epub 2021 Apr 8.

Department of Urology and Renal Transplantation, University of Foggia-Ospedali Riuniti of Foggia, Foggia, Italy.

Purpose: To determine the need for routine bladder biopsies (BBs) in assessing response to the induction cycle of intravesical bacillus Calmette-Guérin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC).

Methods: Our prospectively maintained NMIBC database was queried to identify patients with high-risk disease (carcinoma in situ, high-grade Ta/T1) who underwent BBs after BCG induction cycle. Urine cytology, cystoscopy, and BBs findings were evaluated. Read More

View Article and Full-Text PDF

[A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].

Sichuan Da Xue Xue Bao Yi Xue Ban 2021 Mar;52(2):326-333

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.

Objective: To explore the best treatment plan of intravesical instillation for patients with non-muscular invasive bladder cancer (NMIBC), to explore recurrence-related clinicopathological factors after intravesical instillation, and to evaluate the value of the prognosis and prediction models currently used for NMIBC patients.

Methods: Starting from 2016, patients who underwent transurethral resection of bladder tumor (TURBT) in our hospital and who received post-surgery diagnosis of having intermediate or high risks for NMIBC were enrolled in the study. They were randomly assigned to different group sat a ratio of 2∶2∶1 for receiving intravesical instillation therapy of Bacillus Calmette-Guérin (BCG) for 19 times, BCG for 15 times, and epirubicin (EPI) for 18 times. Read More

View Article and Full-Text PDF

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.

Int J Mol Sci 2021 Mar 10;22(6). Epub 2021 Mar 10.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibility reduces successful treatment outcomes in muscle-invasive bladder cancer (MIBC) patients. The effectiveness of PD-1/PD-L1 immune checkpoint inhibitors (ICI) in metastatic disease has stimulated its evaluation as a treatment option in HR-NMIBC and MIBC patients. Read More

View Article and Full-Text PDF

Biomarker-Oriented Therapy in Bladder and Renal Cancer.

Int J Mol Sci 2021 Mar 11;22(6). Epub 2021 Mar 11.

Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.

Treatment of patients with urothelial carcinoma (UC) of the bladder or renal cancer has changed significantly during recent years and efforts towards biomarker-directed therapy are being investigated. Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle invasive bladder cancer (NMIBC) patients, as well as muscle-invasive bladder cancer (MIBC) patients. Meanwhile, efforts to predict tumor response to neoadjuvant chemotherapy (NAC) are still ongoing, and genomic biomarkers are being evaluated in prospective clinical trials. Read More

View Article and Full-Text PDF

Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.

BJU Int 2021 Apr 1. Epub 2021 Apr 1.

UT Southwestern, 5323 Harry Hines Blvd. J8.112, Dallas, TX, 75390-9110, USA.

Purpose: Frequent recurrences and the potential for progression of non-muscle-invasive bladder cancer (NMIBC) demand close surveillance. This prospective study evaluated the performance of Xpert Bladder Cancer Monitor (Xpert) test as a predictor of tumor recurrence.

Patients And Methods: Patients (n=429) undergoing surveillance for NMIBC underwent Xpert, cytology, and UroVysion testing. Read More

View Article and Full-Text PDF

Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.

JAMA Netw Open 2021 Mar 1;4(3):e213800. Epub 2021 Mar 1.

Durham Veterans Affairs Health Care System, Durham, North Carolina.

Importance: Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guérin (BCG) therapy.

Objective: To describe real-world patient characteristics, long-term outcomes, and the economic burden in a population with high-risk NMIBC treated with BCG therapy.

Design, Setting, And Participants: This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015. Read More

View Article and Full-Text PDF

Time Interval from Transurethral Resection of Bladder Tumor to BCG Induction Does Not Impact Therapeutic Response.

BJU Int 2021 Mar 30. Epub 2021 Mar 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston.

Objectives: To investigate BCG tolerability and response with respect to timing of BCG administration following TUR in patients with non-muscle invasive bladder cancer (NMIBC).

Patients And Methods: A review of NMIBC patients at our institution managed with at least 'adequate BCG' (defined by the US FDA as at least 5/6 induction instillations with 2 additional instillations comprising either maintenance or repeat induction) at our institution from 2000-2018 was performed. Time from TUR to first instillation of induction BCG was stratified by quartile and analyzed as a continuous variable. Read More

View Article and Full-Text PDF

Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.

Minerva Urol Nephrol 2021 Mar 29. Epub 2021 Mar 29.

Urology Department, Sant'Andrea Hospital, Università degli Studi di Roma La Sapienza, Rome, Italy.

Introduction: High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. Read More

View Article and Full-Text PDF

Single course of intravesical Bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study.

Urol Ann 2020 Oct-Dec;12(4):360-365. Epub 2020 Oct 15.

Department of Urology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Objective: The objective of the study was to compare maintenance versus single course of intravesical Bacillus Calmette-Guerin (BCG) in the management of high-risk nonmuscle invasive bladder cancer (NMIBC) regarding recurrence, progression, survival, and complications.

Patients And Methods: After transurethral resection of bladder tumor (TURBT), Group I patients (33) received weekly doses of 90 mg of live attenuated Pasteur strain of BCG. The course was started 14 days after the second TURBT for 6 consecutive weeks. Read More

View Article and Full-Text PDF
October 2020

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?

World J Urol 2021 Mar 27. Epub 2021 Mar 27.

University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Paris, France.

Purpose: Bacille Calmette-Guérin (BCG) is a well-established treatment for preventing or delaying tumour recurrence following high-grade nonmuscle invasive bladder cancer (NMIBC) resection. However, many patients will experience recurrence or progression during or following BCG. This scenario has been one of the most challenging in urologic oncology for several decades since BCG implementation. Read More

View Article and Full-Text PDF

International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma.

Eur Urol Focus 2021 Mar 23. Epub 2021 Mar 23.

Indiana University School of Medicine, Indianapolis, IN, USA.

Context: Grading is the mainstay for treatment decisions for patients with non-muscle-invasive bladder cancer (NMIBC).

Objective: To determine the requirements for an optimal grading system for NMIBC via expert opinion.

Evidence Acquisition: A multidisciplinary working group established by the International Society of Urological Pathology reviewed available clinical, histopathological, and molecular evidence for an optimal grading system for bladder cancer. Read More

View Article and Full-Text PDF

Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?

Urol Oncol 2021 Mar 22. Epub 2021 Mar 22.

Department of Medical Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Introduction: The standard of care for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) patients is transurethral resection of bladder tumor followed by intravesical adjuvant immunotherapy with Bacillus Calmette-Guerin (BCG). However, a non-negligible portion of patients is doomed to fail BCG-therapy and, consequently, undergo radical cystectomy as only treatment option available. In this context, effective options to improve tumor response, thus delaying or even avoiding radical cystectomy, are urgently needed. Read More

View Article and Full-Text PDF

Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients.

Arab J Urol 2020 Aug 31;19(1):71-77. Epub 2020 Aug 31.

Department of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy.

Objective: To evaluate the effectiveness of electro-mediated drug administration of mitomycin C (EMDA/MMC) after transurethral resection of the bladder tumour (TURBT) in preventing non-muscle-invasive bladder cancer (NMIBC) recurrence and progression and to explore clinical and demographic factors associated with treatment response.

Patients And Methods: Between April 2016 and August 2019, 112 patients diagnosed with intermediate- or high-risk NMIBC underwent a TURBT followed by an EMDA/MMC treatment. The percentage of treatment responders and progression-free survivors at 3 and 6 months were evaluated. Read More

View Article and Full-Text PDF

Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.

Eur Urol Focus 2021 Mar 21. Epub 2021 Mar 21.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address:

Context: Patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) may pose a clinical dilemma without an agreed evidence-based decision tree for personalized treatment.

Objective: To perform a systematic review and network meta-analysis (NMA) to summarize available evidence on the oncologic outcomes of intravesical therapy in patients with intermediate-risk NMIBC.

Evidence Acquisition: The MEDLINE, EMBASE, and ClinicalTrials. Read More

View Article and Full-Text PDF

Diagnostic value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update.

Ther Adv Urol 2021 Jan-Dec;13:1756287221997183. Epub 2021 Mar 5.

Department of Urology, Bolzano General Hospital, Lorenz Böhler St 5, Bolzano, 39100, Italy.

Aims: Xpert Bladder Cancer Monitor is a urinary marker based on the evaluation of five target mRNAs overexpressed in patients with bladder cancer (BC). The aim of our study is to update our results regarding the diagnostic accuracy of the Xpert Bladder Cancer Monitor test in the follow-up of patients with non-muscle invasive bladder cancer (NMIBC).

Methods: We conducted a prospective study on 1015 samples of 416 patients (mean age 72. Read More

View Article and Full-Text PDF

The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.

Curr Opin Urol 2021 May;31(3):178-187

Mayo Clinic, Department of Urology, Rochester, Minnesota, USA.

Purpose Of Review: Although radical cystectomy represents the gold standard treatment for patients with high-risk nonmuscle invasive bladder cancer (NMIBC) whose disease does not respond to bacillus Calmette-Guérin (BCG), many patients are unable or unwilling to undergo surgery. The need remains for effective bladder-preserving therapies. This review aims to describe existing treatments, contemporary research in this field and ongoing trials of salvage therapies for patients with BCG-unresponsive NMIBC. Read More

View Article and Full-Text PDF

Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications.

Oncology 2021 Mar 18:1-14. Epub 2021 Mar 18.

Urology Unit, University of Foggia, Bonomo Teaching Hospital, Foggia, Italy.

Background: The most common bladder cancer (BC) histotype is pure urothelial carcinoma (UC), which may undergo divergent differentiation in some cases. Variant histology (VH) presents along variable morphologies, either single or combined between them or with pure UC. From a clinical standpoint, the vast majority of BC is diagnosed at non-invasive or minimally invasive stages, namely as non-muscle invasive BC (NMIBC). Read More

View Article and Full-Text PDF

Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.

Transl Androl Urol 2021 Feb;10(2):626-635

Urology Section, Department of Surgery, University of Catania, Catania, Italy.

Background: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation. Read More

View Article and Full-Text PDF
February 2021

Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.

Ther Adv Urol 2021 Jan-Dec;13:1756287221995683. Epub 2021 Feb 27.

Department of Surgical, Oncological and Oral Sciences, Section of Urology, University of Palermo, Palermo, Sicilia, Italy.

Background: A marker of urothelial damage could be helpful for early detection and monitoring of local toxicity due to intravesical therapy for non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the correlation between fibronectin (FN) gene expression in bladder washings and local toxicity secondary to adjuvant intravesical therapy.

Materials And Methods: Patients undergoing adjuvant intravesical therapy for NMIBC and age-matched healthy patients were enrolled. Read More

View Article and Full-Text PDF
February 2021

STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.

Urol Oncol 2021 Mar 9. Epub 2021 Mar 9.

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC. Electronic address:

Objective: Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC. Read More

View Article and Full-Text PDF

Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.

Photodiagnosis Photodyn Ther 2021 Mar 9:102248. Epub 2021 Mar 9.

Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, Zhejiang, China. Electronic address:

Background: The benefits of fluorescent light (FL) cystoscopy with 5-aminolevulinic acid (5-ALA) or hexaminolevulinate (HAL) in non-muscle-invasive bladder cancer (NMIBC) have been mentioned in many trials. Meanwhile, several problems need to be addressed.

Objective: To assess the effects of FL cystoscopy compared with white light (WL) cystoscopy on the rate of residual Ta, T1, and carcinoma in situ (CIS) tumors, recurrence-free survival (RFS) and progression-free survival (PFS). Read More

View Article and Full-Text PDF

Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.

BMC Cancer 2021 Mar 11;21(1):266. Epub 2021 Mar 11.

Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Background: To explore possible solutions to overcome chronic Bacillus Calmette-Guérin (BCG) shortage affecting seriously the management of non-muscle invasive bladder cancer (NMIBC) in Europe and throughout the world, we investigated whether non-maintenance eight-dose induction BCG (iBCG) was comparable to six-dose iBCG plus maintenance BCG (mBCG).

Methods: This observational study evaluated 2669 patients with high- or highest-risk NMIBC who treated with iBCG with or without mBCG during 2000-2019. The patients were classified into five groups according to treatment pattern: 874 (33%) received non-maintenance six-dose iBCG (Group A), 405 (15%) received six-dose iBCG plus mBCG (Group B), 1189 (44%) received non-maintenance seven-/eight-dose iBCG (Group C), 60 (2. Read More

View Article and Full-Text PDF

Intravesical Recurrence After Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes.

Front Surg 2021 22;8:590448. Epub 2021 Feb 22.

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.

Of patients with upper urinary tract urothelial carcinoma (UTUC), 22-47% developed bladder recurrence after radical nephroureterectomy. Furthermore, the effect of surgery for UTUC-bladder cancer (BC) has not been well validated. The aim of this study was to assess the impact of standard primary BC surgical strategy on survival of patients diagnosed with UTUC-BC. Read More

View Article and Full-Text PDF
February 2021

Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns.

Curr Med Chem 2021 Mar 8. Epub 2021 Mar 8.

Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow 117418. Russian Federation.

Objective: The molecular mechanisms of bladder cancer development and progression are not clear. Bladder cancer is an important focus for epidemiological studies and understanding clinical implications.

Goal: The primary aim of prevention is achieved by limiting exposure to non-genetic risk factors such as smoking, diet, arsenic in drinking water, or aromatic amines at work or elsewhere. Read More

View Article and Full-Text PDF

Impact of enhanced optical techniques at time of TURBT with or without single immediate intravesical chemotherapy on recurrence rate of NMIBC, a systematic review and network meta-analysis of randomized trials.

BJU Int 2021 Mar 8. Epub 2021 Mar 8.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Introduction: The novel optical techniques such as blue light cystoscopy (BLC) during transurethral resection of bladder tumor (TURBT) has been shown to improve the tumor detection rate and recurrence rate. Whether a single immediate intravesical chemotherapy (SIIC) still has an additive therapeutic effect in the setting of these novel optical techniques (e.g. Read More

View Article and Full-Text PDF

Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.

J Cancer Res Clin Oncol 2021 Mar 6. Epub 2021 Mar 6.

Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

Purpose: (I) To evaluate the clinical efficacy of three different BCG strains in patients with intermediate-/high-risk non-muscle-invasive bladder cancer (NMIBC). (II) To determine the importance of performing routine secondary resection (re-TUR) in the setting of BCG maintenance protocol for the three strains.

Methods: NMIBCs who received an adjuvant induction followed by a maintenance schedule of intravesical immunotherapy with BCG Connaught, TICE and RIVM. Read More

View Article and Full-Text PDF

Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer.

Ann Surg Oncol 2021 Mar 5. Epub 2021 Mar 5.

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Introduction: Our aim is to evaluate whether previous non-urothelial malignant history affects the clinical outcomes of patients with non-muscle invasive bladder cancer (NMIBC).

Patients And Methods: We identified 1097 cases treated by transurethral resection of bladder tumors for initially diagnosed NMIBC at our four institutions between 1999 and 2017. We compared clinical characteristics and outcomes between NMIBC patients with and without previous non-urothelial malignant history and investigated whether smoking status and treatment modality for previous cancer affected NMIBC outcomes. Read More

View Article and Full-Text PDF